ClinicalTrials.gg
CompletedNCT05587062Updated Feb 14, 2023

Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration

A Phase 3 interventional study of Aflibercept (CinnaGen Co, Iran) and Aflibercept (Regeneron, USA) in Age-Related Macular Degeneration and Neovascular Age-related Macular Degeneration, sponsored by Cinnagen. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 55 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-14.

Sponsored by Cinnagen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Oct 2019, registered Sep 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
18th of 66
168 · median 55
Started
2019
with 3 others
Phase 3
18 of 66
1 open now
Registered
55th of 66
by date

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 18th largest by enrollment, is one of 4 that started in 2019, is one of 18 in phase 3, and was the 55th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 55 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Aflibercept (produced by CinnaGen Co, Iran) compared with Eylea® (Regeneron, USA) in subjects with Neovascular Age-related Macular Degeneration (nAMD).

All the participants will receive one of the following regimens:

Aflibercept (CinnaGen Co, Iran) or Eylea® (Regeneron, USA), 2 mg (vial 0.05 ml) by intravitreal injection every 4 weeks for the first 3 injections, followed by 2 mg every 8 weeks until week 48 of study.

The primary objective of this study is to verify the non-inferiority of Aflibercept (CinnaGen Co, Iran) versus Eylea® (Regeneron, USA) in achieving maintaining vision (losing\<15 letter on ETDRS chart) at week 52 in comparison to week 0 in participants with Neovascular AMD.

03

Conditions studied

  • Age-Related Macular Degeneration
  • Neovascular Age-related Macular Degeneration

Keywords

  • AMD
  • nAMD
  • Recombinant Fusion Protein
  • anti-VEGF
  • Aflibercept
04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 55-80 years at the time of signing the form.
  2. Primary active CNV subfoveal lesion secondary to AMD, with definite diagnosis of AMD, according to the physician's decision, based on the results of ocular examination, or OCT, based on the following diagnostic Criteria:

    • Evaluating the presence of Submacular hemorrhage in fundus examination with the presence of any of those items mentioned in OCT including: subretinal fluid, subretinal hyper reflective material, intraretinal fluid or pigment epithelial detachment.

    Or

    • Diagnosis of the following, based on the OCT evaluations:
    • Presence of pigment epithelial detachment with intra-retinal fluid and subretinal fluid
    • Presence of pigment epithelial detachment with intra-retinal fluid and subretinal hyper reflective material

    The presence of new vessels should be confirmed with one of the additional imaging modalities (FA or ICG or OCTA).

    In cases with any suspicious for the diagnosis of AMD, other confirmatory modalities should be used.

  3. The ETDRS-best-corrected visual acuity index with the score of 20/40 to 20/320 (or BCVA letter score of 73 to 25 in the study eye), which is determined by a specific trained person, within the standard distance, in each study center.
  4. Willing, committed, and able to return for clinic visits and complete all study-related procedures.
  5. Patients with the ability to read, (or, if unable to read due to visual impairment, be read by a family member or person administering the informed consent form) understand and willing to sign the informed consent form for participation in the study.

Exclusion criteria

Exclusion Criteria:

  1. Any prior ocular or systemic anti-VEGF therapy, during the past three months, Photodynamic Therapy (PDT) or surgery for neovascular AMD.
  2. The need for receiving ocular anti-VEGF simultaneously in both eyes in the loading phase for the treatment of neovascular AMD (in fact, if the patient, in addition to the study eye, also needs to receive the drug for the opposite eye)
  3. Scar, fibrosis, or extensive subretinal hemorrhage of more than 50% of the total lesion area in the study eye, according to the physician's opinion based on clinical presentation or according to fundus photography.
  4. The presence of scar, fibrosis, or atrophy in the central part of the fovea in the study eye.
  5. The presence of retinal pigment epithelial tears or rips involving the macular part of the study eye at the time of entering the study.
  6. The history of any vitreous hemorrhage within four weeks prior to the first visit of the study in the study eye.
  7. Presence of other causes of CNV, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25 mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study eye.
  8. Clinical or paraclinical diagnosis of PCV by the physician at baseline
  9. The history or clinical evidence of diabetic retinopathy, diabetic macular edema, or any other vascular disease affecting the retina, other than AMD in either eyes.
  10. Prior vitrectomy in the study eye.
  11. History of retinal detachment or treatment or surgery for retinal detachment in the study eye.
  12. Any history of a macular hole of stage two or above in the study eye.
  13. Any intraocular or periocular surgery within three months of the screening visit on the study eye except lid surgery, which may not have taken place within one month of screening visit, as long as it's unlikely to interfere with the injection during the study.
  14. Prior trabeculectomy or any other filtration surgery in the study eye.
  15. Uncontrolled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma medication) in the study eye.
  16. Active intraocular inflammation in either eye.
  17. Active ocular or periocular infection in either eye
  18. Any ocular or periocular infection within the last two weeks prior to screening visit in either eye.
  19. Any history of uveitis in either eye.
  20. Presence or history of scleromalacia in either eye.
  21. Aphakia or pseudophakia with the absence of posterior capsule (unless it occurred as a result of a yttrium aluminum garnet [YAG] posterior capsulotomy) in the study eye.
  22. Previous therapeutic radiation in the region of the study eye.
  23. History of corneal transplant or corneal dystrophy in the study eye.
  24. Any significant media opacities, including cataract, in the study eye that might interfere with visual acuity, assessment of drug safety, or fundus photography.
  25. Patients with amblyopia.
  26. Patients with blindness in the opposite eye (if for any reason, the patient's vision in the opposite eye is limited to understanding the light and movement of the hands, the patient should not enter the study, but if the best-corrected visual acuity index is 20/400 or more, it is not a problem).
  27. Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could require either medical or surgical intervention during the study period.
  28. Any concurrent ocular condition in the study eye which, in the opinion of the investigator, could either increase the risk to the patient beyond what is to be expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety.
  29. History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an drug or that might affect the interpretation of the results of the study or render the patient at high risk for treatment complications.
  30. Participation as a patient in any clinical study within the 12 weeks prior to the screening visit.
  31. The use of long-acting , either systemically or intraocularly, in the six months prior to screening visit.
  32. Any history of allergy to povidone iodine.
  33. Females who are pregnant, breastfeeding, planning to become pregnant during the study period, unwilling to practice adequate throughout the study and for at least 60 days following the last dose of study medication.
  34. History of stroke, myocardial infarction or uncontrolled hypertension (blood pressure >160/100 despite receiving medical treatment) for less than three months from the date of the Screening visit.
  35. Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    Aflibercept (CinnaGen Co, Iran)

    Aflibercept (CinnaGen Co, Iran) 2 mg (0.05 mL) by intravitreal injection every 4 weeks for the first 3 injections, followed by 2 mg every 8 weeks until week 48 of study

    Biological: Aflibercept (CinnaGen Co, Iran)

  • Active comparator
    Aflibercept (Regeneron, USA)

    Aflibercept (Regeneron, USA) 2 mg (0.05 mL) by intravitreal injection every 4 weeks for the first 3 injections, followed by 2 mg every 8 weeks until week 48 of study

    Biological: Aflibercept (Regeneron, USA)

Interventions

06

What researchers measure

Primary outcomes

  1. The proportion of patients achieving maintaining vision at week 52

    Achieving maintaining vision confirmed by losing\<15 letter on ETDRS chart

    Time frame: At week 52

Secondary outcomes

  1. Mean changes in the Best-Corrected Visual Acuity Index from week 0 to week 52

    Changes in Best-Corrected Visual Acuity Index measured with ETDRS chart

    Time frame: Baseline and at week 52

  2. The percentage of patients who have increase of ≥15 score in ETDRS at week 52 compared to week 0

    Increase of ≥15 score in ETDRS chart demonstrates improvement in visual function

    Time frame: Baseline and at week 52

  3. The mean change in National Eye Institute Visual Function Questionnaire (NEI VFQ-25) at week 52 compared to week 0

    The NEI VFQ-25 (National Eye Institute Visual Functioning Questionnaire) is a self-reported vision-targeted health status which has importance value in chronic eye diseases. Total score range is from 0 to 100. In this scale, score of 0 demonstrates the worst outcome and 100 means the best outcome. The NEI VFQ -25 has a collection of subscales which are all scored from 0-100. The overall score is average of all subscale in order to give each sub-scale equal weight.

    Time frame: Baseline and at week 52

  4. Mean changes in central retinal thickness at week 52 compared to the screening visit

    Retinal thickness is measured by Optical Coherence Tomography (OCT) which shows disease activity in Neovascular Age-related Macular Degeneration

    Time frame: Baseline and at week 52

  5. The percentage of patients without intra-retinal fluid and subretinal fluid at week 52

    Intra-retinal fluid and subretinal fluid measured with Optical Coherence Tomography (OCT)

    Time frame: Baseline and at week 52

  6. Number of participants with Adverse Events (AEs)

    Systemic and ophthalmic Adverse Events (AEs) and Adverse Drug Reactions (ADR) at baseline, all the visits to the end of week 52, evaluation of vital sign including blood pressure and physical examination findings at baseline and at week 52, clinical laboratory testing including liver and kidney functions, complete blood count, and clinical bio-chemistries and immunogenicity assessment at baseline, week 24 and week 52

    Time frame: Baseline up to Week 52

07

Study locations

1 site
  • Farabi Hospital
    Tehran, Iran, Islamic Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Jul 2022, 33 months.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 33 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2022
First posted
Oct 19, 2022
StartActual
Oct 1, 2019
Primary completionActual
Jul 31, 2022
CompletionActual
Jul 31, 2022
Last update
Feb 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05587062
Lead sponsor
Cinnagen
Responsible party
Sponsor
First posted
Oct 19, 2022
Start date
Oct 1, 2019
Primary completion
Jul 31, 2022
Completion
Jul 31, 2022
Last update
Feb 14, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion